Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing vitreous opacity

A technology of vitreous opacity and composition, which is applied in the direction of drug combinations, active ingredients of heterocyclic compounds, and pharmaceutical formulations, and can solve problems such as slow metabolism, complicated etiology and pathogenesis, and difficult to cure

Inactive Publication Date: 2017-05-17
JINAN HAOYU QINGTIAN PHARMA TECH CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] The vitreous body itself has no blood vessels, and its metabolism is very slow. The vitreous body is mostly caused by lesions in the surrounding tissues. The pathological process is turbidity, liquefaction, fibrous tissue formation and contraction. The classification is called inflammatory turbidity caused by inflammation, and hemorrhagic turbidity caused by bleeding. Opacity, caused by degenerative changes, is called degenerative turbidity. Inflammatory vitreous opacity is mostly caused by iridocyclitis, choroiditis (uveitis), retinitis and other inflammatory cells, exudates and pathological products such as necrotic tissue It is caused by entering the vitreous body. The opacity caused by iridocyclitis is mainly anterior; the opacity caused by retinitis and choroiditis is mainly posterior. Its shape can be dusty, silky, fluffy, lumpy or Cord-shaped, grayish-white dot-like or white flocculent, snowball-like turbidity, hemorrhagic vitreous opacity refers to visual impairment complications caused by ocular trauma or retinal vascular disease, when the amount of bleeding is large, it is equivalent to sudden blindness in traditional Chinese medicine , the red light reflection of the fundus disappears, the fundus cannot be seen, and the vision is light perception. Under the ophthalmoscope, there are cord-like and fast-like opacities in the vitreous body. Degenerative vitreous opacities are more common in the elderly with high myopia, and there are also young people with the disease. The higher the degree of myopia, the earlier the age of onset, and there are also changes such as degeneration, turbidity and liquefaction caused by inflammation and bleeding. In short, vitreous opacity is not a single disease. The etiology and pathogenesis are complex, and it is difficult to cure with western medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing vitreous opacity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1: the pharmaceutical composition and preparation method thereof of preventing and treating vitreous opacity

[0039] The composition and parts by weight of the raw materials of the pharmaceutical composition for preventing and treating vitreous opacity are: 4850g of syringa, 65g of katydid, 3600g of asterite, 60g of cucurbitacin L, 105g of Agrimony lactone, and 65g of sophorin;

[0040] Preparation:

[0041] (1) According to the ratio of raw materials, take katydid, asterite, yizhuxiang, cucurbitacin L, agrilactone, and sophorin, mix them evenly, use ethanol with a concentration of 49% by weight as a solvent, and warm at 30.5°C Dipping extraction, the number of times of extraction is 25 times, each extraction time is 17 hours, and the amount of solvent is 44 times of the total weight of the crude drug each time, filtering to obtain medicinal residue A and extract A, extract A reclaims ethanol, concentrates to The relative density is 1.04, filtered, the drug...

Embodiment 2

[0044] Embodiment 2: the pharmaceutical composition of preventing and treating vitreous opacity and preparation method thereof

[0045] The composition and parts by weight of the raw materials of the pharmaceutical composition for preventing and treating vitreous opacity are: 4800g of syringa, 3500g of katydid 80g, 3500g of cucurbitacin L70g, 100g of agrimones, and 70g of sophorin;

[0046] Preparation:

[0047] (1) According to the ratio of raw materials, take katydid, asterite, yizhuxiang, cucurbitacin L, agrilactone, and sophorin, mix them evenly, use ethanol with a concentration of 49% by weight as a solvent, and warm at 30.5°C Dipping extraction, the number of times of extraction is 25 times, each extraction time is 17 hours, and the amount of solvent is 44 times of the total weight of the crude drug each time, filtering to obtain medicinal residue A and extract A, extract A reclaims ethanol, concentrates to The relative density is 1.04, filtered, the drug solution passe...

Embodiment 3

[0050] Embodiment 3: the pharmaceutical composition and preparation method thereof of preventing and treating vitreous opacity

[0051] The composition and parts by weight of the raw materials of the medicinal composition for preventing and treating vitreous opacity are: 4900g of syringa, 50g of katydid, 3700g of asterite, 40g of cucurbitacin L, 110g of Agrimony lactone, and 60g of sophorin;

[0052] Preparation:

[0053] (1) According to the ratio of raw materials, take katydid, asterite, yizhuxiang, cucurbitacin L, agrilactone, and sophorin, mix them evenly, use ethanol with a concentration of 49% by weight as a solvent, and warm at 30.5°C Dipping extraction, the number of times of extraction is 25 times, each extraction time is 17 hours, and the amount of solvent is 44 times of the total weight of the crude drug each time, filtering to obtain medicinal residue A and extract A, extract A reclaims ethanol, concentrates to The relative density is 1.04, filtered, the drug solu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for preventing vitreous opacity and a preparation method thereof. The pharmaceutical composition is prepared by proportioning raw material medicines of common anotis herbs, grasshopper, trachelospermum axillare, cucurbitacin L, agrimonolide and cnidium officinale makino, and can be prepared into various dosage forms according to a conventional preparation technology, and the curative effect of preventing vitreous opacity is significant.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a pharmaceutical composition for preventing and treating vitreous opacity and a preparation method thereof. Background technique [0002] The vitreous body itself has no blood vessels, and its metabolism is very slow. The vitreous body is mostly caused by lesions in the surrounding tissues. The pathological process is turbidity, liquefaction, fibrous tissue formation and contraction. The classification is called inflammatory turbidity caused by inflammation, and hemorrhagic turbidity caused by bleeding. Opacity, caused by degenerative changes, is called degenerative turbidity. Inflammatory vitreous opacity is mostly caused by iridocyclitis, choroiditis (uveitis), retinitis and other inflammatory cells, exudates and pathological products such as necrotic tissue It is caused by entering the vitreous body. The opacity caused by iridocyclitis is main...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/74A61P27/02A61K35/64A61K31/575A61K31/37A61K31/36
CPCA61K36/74A61K31/36A61K31/37A61K31/575A61K35/63A61K36/24A61K2236/333A61K2236/39A61K2236/51A61K2236/55A61K2300/00
Inventor 不公告发明人
Owner JINAN HAOYU QINGTIAN PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products